COVID-19, influenza, and respiratory syncytial virus vaccination coverage is low among adults so far this respiratory virus season (2024 to 2025).

Seasonal maternal respiratory syncytial virus vaccination and nirsevimab for infants demonstrate cost-effectiveness.

RSV remains a major cause of hospitalization among children, according to a population-based Canadian Immunization Research ...

Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness,” published in the November 2024 issue ...

So far very few Americans have been rolling up their sleeves to get vaccinated against COVID, flu or RSV. Rob Stein is a correspondent and senior editor on NPR's science desk.